Form 4: Moderna CLO Klinger Reports RSU Conversion, Tax Withholding

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the conversion of restricted stock units into common stock and subsequent tax-related share disposals.

Summary

• Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., reported transactions involving company common stock and restricted stock units (RSUs).
• On December 1, 2025, 233 restricted stock units converted into 233 shares of Moderna common stock on a one-for-one basis.
• Following this conversion, 113 shares of common stock were disposed of at a price of $25.98 per share to satisfy tax withholding obligations related to the RSU vesting.
• After these reported transactions, Klinger directly beneficially owns 28,858 shares of Moderna common stock.
• The restricted stock unit award began vesting on March 1, 2023, with 25% of the shares vesting then, and the remainder vesting in twelve equal quarterly installments thereafter.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving the vesting of restricted stock units and subsequent tax withholding. This is a standard compensation event and does not indicate significant positive or negative operational news, thus maintaining a neutral to slightly positive sentiment due to continued executive equity alignment.

Positives

• The conversion of restricted stock units into common stock indicates the vesting of equity compensation, which aligns management's financial interests with those of shareholders.

Negatives

• A portion of the vested shares (113 shares) was sold to cover tax withholding obligations, which, while a common practice, reduces the direct equity holding of the reporting person.

Industry Context

This filing details a routine insider transaction, specifically the vesting and conversion of equity compensation for a senior executive. Such events are common across publicly traded companies and reflect standard practices for executive remuneration, rather than providing insights into broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The practice of granting restricted stock units (RSUs) as a form of executive compensation is a widely adopted standard across various industries, including biotechnology and pharmaceuticals, aligning executive incentives with long-term shareholder value.
• The subsequent sale of a portion of vested shares to cover tax withholding obligations is also a standard and expected procedure for equity compensation in the U.S., consistent with practices observed at comparable companies like Pfizer or Johnson & Johnson.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation, reinforcing the alignment of the Chief Legal Officer's interests with shareholders through equity ownership. The sale for tax purposes is a common practice and has a minimal dilutive effect.
• Employees: Reflects standard equity compensation practices for executives within the company.

Next Steps

• The remaining restricted stock units subject to this award will continue to vest in twelve equal quarterly installments after March 1, 2023.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the vesting of restricted stock units and subsequent sale of shares for tax withholding purposes. Such transactions are standard for executive compensation and generally do not provide new material information to warrant a change in investment recommendation. The underlying business fundamentals of Moderna, Inc. remain the primary drivers for investment decisions.

Keywords

Moderna, MRNA, Shannon Thyme Klinger, Chief Legal Officer, Insider Transaction, Form 4, Restricted Stock Units, RSU Conversion, Equity Compensation, Tax Withholding